• Release your full potential

    Be free to be active. Pioneering new territory to set new standards

ABOUT US

Pioneering novel treatment paradigms within immunology and inflammation (“I&I”). Read more about MC2 Therapeutics.

Platform

Our two first-in-class and novel mode of action drug candidates are “I&I pipeline in a drug” as they both have potential in multiple major underserved indications. We carefully select indications based on science, clinical unmet need and market access. Read more about our platform.

Pipeline

Based on our two first-in-class and novel mode of action drug candidates, we are currently pursuing indications where there are no or very limited approved treatment options. This includes MC2-32 a first-in-class oral HSP90 Inhibitor for Hidradenitis Suppurativa (Ph2a completed) and MC2-25 a topical first-in-class iso-cyanate scavenger for Vulvar Lichen Sclerosus (Ph2a ongoing). Read more about our pipeline.

LATEST NEWS

mc2_news-image-icon-07

MC2 Therapeutics Announces License and Commercialization Agreement for Wynzora® Cream in Canada

Copenhagen, November 14, 2024 – MC2 Therapeutics, a commercial stage biotech company focused on developing ...

READ FULL ARTICLE

CEO Jesper J. Lange awarded as CEO of the Year

On June 18th, 2024 our CEO, Jesper J. Lange, received the award ...

READ FULL ARTICLE

 

mc2_news-image-icon-07

MC2 Therapeutics Receives Positive Feedback from FDA pre-IND Meeting and Updates on Indication Expansion Strategy

  • On track to file IND in mid-2025 for a Phase 2b clinical trial in Hidradenitis Suppurativa ...

    READ FULL ARTICLE

mc2_news-image-icon-05

MC2 Therapeutics Announces License, Supply and Commercialization Agreement for Wynzora® Cream in ASEAN Countries

Copenhagen, March 12th, 2024 – MC2 Therapeutics, a commercial stage biotech company focused on developing ...

READ FULL ARTICLE